Britain Backs GSK’s Gene Therapy for ‘Bubble Boy’ Syndrome – New York Times
|
Britain Backs GSK's Gene Therapy for 'Bubble Boy' Syndrome
New York Times Britain's National Institute for Health and Care Excellence (NICE) said in draft guidance published on Friday that Strimvelis gene therapy used against adenosine deaminase deficiency, or ADA-SCID, improves overall survival compared with standard stem … |
